Search

The paper examines the prospects of using laser plasma as a source of high-energy ions for the purpose of hadron beam therapy -- an approach which is based on both theory and experimental results (ions are routinely observed to be accelerated in the interaction of high-power laser radiation with matter). Compared to therapy accelerators like synchrotrons and cyclotrons, laser technology is advantageous in that it is more compact and is simpler in delivering ions from the accelerator to the treatment room. Special target designs allow radiation therapy requirements for ion beam quality to be satisfied.

We present the first observation of ultracold LiCs molecules. The molecules are formed in a two-species magneto-optical trap and detected by two-photon ionization and time-of-flight mass spectrometry. The production rate coefficient is found to be in the range 10?18cm3s?1to 10?16cm3s?1, at least an order of magnitude smaller than for other heteronuclear diatomic molecules directly formed in a magneto-optical trap.

The paper examines the prospects of using laser plasma as a source of high-energy ions for the purpose of hadron beam therapy — an approach which is based on both theory and experimental results (ions are routinely observed to be accelerated in the interaction of high-power laser radiation with matter). Compared to therapy accelerators like synchrotrons and cyclotrons, laser technology is advantageous in that it is more compact and is simpler in delivering ions from the accelerator to the treatment room. Special target designs allow radiation therapy requirements for ion beam quality to be satisfied.